Results 51 to 60 of about 575,729 (287)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

On Entropy Test for Conditionally Heteroscedastic Location-Scale Time Series Models

open access: yesEntropy, 2017
This study considers the goodness of fit test for a class of conditionally heteroscedastic location-scale time series models. For this task, we develop an entropy-type goodness of fit test based on residuals.
Sangyeol Lee, Minjo Kim
doaj   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Applying the M2 Statistic to Evaluate the Fit of Diagnostic Classification Models in the Presence of Attribute Hierarchies

open access: yesFrontiers in Psychology, 2018
The performance of the limited-information statistic M2 for diagnostic classification models (DCMs) is under-investigated in the current literature. Specifically, the investigations of M2 for specific DCMs rather than general modeling frameworks are ...
Fu Chen, Yanlou Liu, Tao Xin, Ying Cui
doaj   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

open access: yesMolecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck   +12 more
wiley   +1 more source

New L2-type exponentiality tests [PDF]

open access: yes, 2019
We introduce new consistent and scale-free goodness-of-fit tests for the exponential distribution based on the Puri-Rubin characterization. For the construction of test statistics we employ weighted L2 distance between V-empirical Laplace transforms of ...
Cuparić, Marija   +2 more
core  

On APF Test for Poisson Process with Shift and Scale Parameters

open access: yes, 2018
We propose the goodness of fit test for inhomogeneous Poisson processes with unknown scale and shift parameters. A test statistic of Cramer-von Mises type is proposed and its asymptotic behavior is studied.
Dabye, A. S.   +2 more
core   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

open access: yesMolecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken   +3 more
wiley   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

open access: yesMolecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy